E-Posters (Trials In Progress)

TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer

Pub Date : 2022-12-01 DOI: 10.1136/ijgc-2022-igcs.539 P. Konstantinopoulos, A. González-Martín, F. Cruz, M. Friedlander, R. Glasspool, D. Lorusso, C. Marth, B. Monk, Jae-Weon Kim, Olga Ajipa, F. Su, Yu Han, U. Matulonis

TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma

Pub Date : 2022-12-01 DOI: 10.1136/ijgc-2022-igcs.525 B. Slomovitz, D. Cibula, M. Gultekin, M. Mirza, B. Maćkowiak-Matejczyk, A. Taylor, I. Romero, N. Colombo, J. Korach, Jianqing Zhu, L. Gilbert, K. Hasegawa, Jae-Weon Kim, S. Baron-Hay, V. Makker, R. Coleman, R. Orlowski, Xuan Zhou, V. Khemka, S. Pignata

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018)

Pub Date : 2022-12-01 DOI: 10.1136/ijgc-2022-igcs.549 F. Damian, G. D. Molin, A. Rodrigues, A. Calabrich, G. Werutsky, E. A. Filho, M. F. Jiménez, T. Rebelatto, R. D. Jesus, A. Melo